Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLO1 | Q04760 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17339986 | 0.81 | TSHR (0.48) | ALDH1A1 | |
| SCHEMBL6572365 | 0.79 | — | — | |
| SCHEMBL16433403 | 0.76 | ALDH1A1 (0.37) | GLO1ALDH1A1LMNAHSD17B10 | |
| SCHEMBL27654348 | 0.76 | GLO1 (0.36) | GLO1ALDH1A1LMNAHSD17B10 | |
| SCHEMBL13334145 | 0.75 | — | — | |
| SCHEMBL22582940 | 0.75 | ALDH1A1 (0.40) | GLO1ALDH1A1LMNAHSD17B10 | |
| SCHEMBL27707063 | 0.74 | GLO1 (0.34) | GLO1ALDH1A1LMNAHSD17B10 | |
| SCHEMBL27823858 | 0.74 | GLO1 (0.34) | GLO1ALDH1A1LMNAHSD17B10 | |
| SCHEMBL27820684 | 0.74 | GLO1 (0.34) | GLO1ALDH1A1LMNAHSD17B10 | |
| SCHEMBL3049017 | 0.74 | PAM (0.40) | GLO1ALDH1A1LMNAHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2013078554-A1 | COMPOSITIONS OF TIGECYCLINE AND USES THEREOF | UNIVERSITY HEALTH NETWORK (CA) | 2013-06-06 | — | — | WO | claimed |
| US-8735633-B2 | Methods for making 1,3-dihydroxyacetone (DHA) from glycerol | BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY (US) | 2014-05-27 | — | — | US | disclosed |
| CN-103642863-A | Method of producing l-amino acid | AJINOMOTO KK | 2014-03-19 | — | — | CN | disclosed |
| WO-2014029016-A1 | COMPOSITIONS COMPRISING A GLYCYLCYCLINE AND A TYROSINE KINASE INHIBITOR FOR TREATING CANCER | UNIVERSITY HEALTH NETWORK (CA) | 2014-02-27 | — | — | WO | disclosed |
| CN-101631871-B | Process for producing L-amino acid | AJINOMOTO KK | 2013-09-11 | — | — | CN | disclosed |
| WO-2013078554-A1 | COMPOSITIONS OF TIGECYCLINE AND USES THEREOF | UNIVERSITY HEALTH NETWORK (CA) | 2013-06-06 | — | — | WO | disclosed |
| US-20120014889-A1 | METHODS FOR MAKING 1,3-DIHYDROXYACETONE (DHA) FROM GLYCEROL | BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY | 2012-01-19 | — | — | US | disclosed |
| CN-101631871-A | Process for producing L-amino acid | AJINOMOTO KK | 2010-01-20 | — | — | CN | disclosed |
| WO-2002102348-A1 | ANTI-STRETCH MARK PRODUCT AND CORRESPONDING METHOD | PRISCILLA S.R.L. UNIPERSONALE (IT) | 2002-12-27 | — | — | WO | disclosed |
| WO-2002080880-A2 | ANTI-STRETCH MARK PREPARATION AND METHOD THEREOF | PRISCILLA S.R.L. UNIPERSONALE (IT) | 2002-10-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120014889-A1 | METHODS FOR MAKING 1,3-DIHYDROXYACETONE (DHA) FROM GLYCEROL | DGAT2, ADH1B, ADH1A | GLO1 101/4885ALDH1A1 28/4885LMNA 2432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.